Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Helps you reach and maintain a healthy weight.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 1 to 20 of 60

Orlistat and sibutramine beyond weight loss

This review aimed to assess the effects of orlistat and sibutramine on blood lipids. It concluded that orlistat, but not sibutramine, determined a significant reduction in total cholesterol independent of the weight loss itself. Important information on the methods was missing from the review, so it was impossible to determine whether the conclusions were reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

This review assessed the effects of orlistat on weight loss in overweight patients. The authors concluded that orlistat is effective in improving both weight loss and serum lipid profiles in obese patients at low and high cardiovascular disease risk, and in obese patients with type 2 diabetes. The authors' conclusions are appropriate and appear reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

This review of 22 trials concluded that sibutramine caused significant elevations in diastolic blood pressure especially amongst diabetics but orlistat did not. There were major methodological limitations of the included trials and important potential biases in the conduct and interpretation of the synthesis. The review conclusions are unreliable but the recommendation for further research is well founded.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents

The review concluded that sibutramine and orlistat in combination with a hypocaloric diet and changes in lifestyle in obese adolescents achieve a short-term loss of weight greater than that achieved through the dietary-behavioural therapy alone. The review had methodological and data limitations that limit the reliability of the authors conclusions.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

This review concluded that there was heterogeneity between the drugs in risk rates for drop-out due to adverse effects and underlying causes. The low number needed to harm for rimonabant was of concern. The conclusion reflected the results of the review and appears likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Benefit assessment of non-drug treatment strategies in patients with hypertension: weight reduction: Executive summary of final report A05-21A, Version 1.0

The aim of this report was to assess the benefit of weight-reducing therapeutic interventions as a treatment strategy in patients with hypertension.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: August 31, 2006

Hypertension: Does losing weight reduce high blood pressure?

Losing weight by dieting (with or without exercise) or by using the drug orlistat can lower high blood pressure in the short term. It is not clear whether weight loss alone can protect against long-term harm from hypertension.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: June 6, 2012

Screening for and Management of Obesity and Overweight in Adults [Internet]

Overweight and obesity in adults are common and associated with cardiovascular risk and other adverse health effects.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: October 2011
Show search results within this document

Second- and Third-Line Pharmacotherapy for Type 2 Diabetes: Update [Internet]

In August 2010, the Canadian Agency for Drugs and Technologies in Health (CADTH) published an Optimal Therapy Report which assessed the clinical and cost-effectiveness of second-line therapies for patients with type 2 diabetes inadequately controlled on metformin. The results from the CADTH review indicated that there were no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective treatment option. Based on these analyses, the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) Expert Review Committee (CERC) recommended that most patients requiring a second treatment after metformin should be prescribed a sulfonylurea. CADTH followed this report with a Therapeutic Review which examined the evidence for third-line treatment options for adults with type 2 diabetes inadequately controlled on metformin and a sulfonylurea. The results demonstrated that insulins (basal, biphasic, bolus), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and thiazolidinediones (TZDs) all produced statistically significant reductions in hemoglobin A1C in combination with metformin and a sulphonylurea. Meglitinides and alpha-glucosidase inhibitors, however, did not. The addition of insulin neutral protamine Hagedorn (NPH) to metformin plus a sulfonylurea was associated with the most favourable cost-effectiveness estimates. CADTH’s Therapeutic Review Panel (TRP) recommended that, for most adults with type 2 diabetes inadequately controlled on metformin and a sulfonylurea, insulin NPH should be added as the third-line agent. Long-acting insulin analogues at prices similar to insulin NPH were also considered an option for patients inadequately controlled on metformin and a sulfonylurea.

CADTH Optimal Use Report - Canadian Agency for Drugs and Technologies in Health.

Version: July 2013
Show search results within this document

Fact sheet: Health benefits of losing weight

Being overweight increases the risk of health problems, but what benefits can you expect if you lose weight? Is there an immediate health pay-off, or is it impossible to get quick results? Losing weight and then keeping it off usually takes a lot of motivation, because we really have to change our lifestyles if we want to change our weight for the long term. Changing long-established habits and patterns of behavior is hardly ever easy.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 8, 2012

What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review

Obesity [defined as a body mass index (BMI) ≥ 30 kg/m2] represents a considerable public health problem and is associated with a significant range of comorbidities and an increased mortality risk. The primary aim of the management of obesity is to achieve weight reduction in the interests of health. For obese patients who cannot achieve or maintain a healthy weight by non-pharmacological means, drug therapy is recommended in combination with non-pharmacological interventions such as dietary modifications and exercise.

Health Technology Assessment - NIHR Evaluation, Trials and Studies Coordinating Centre (UK).

Version: February 2012
Show search results within this document

Childhood Obesity Prevention Programs: Comparative Effectiveness Review and Meta-Analysis [Internet]

Childhood obesity is a serious health problem in the United States and worldwide. More than 30 percent of American children and adolescents are overweight or obese. We assessed the effectiveness of childhood obesity prevention programs by reviewing all interventional studies that aimed to improve diet, physical activity, or both and that were conducted in schools, homes, primary care clinics, childcare settings, the community, or combinations of these settings in high-income countries. We also reviewed consumer health informatics interventions. We compared the effects of the interventions on weight-related outcomes (e.g., body mass index [BMI], waist circumference, percent body fat, skinfold thickness, prevalence of obesity and overweight); intermediate outcomes (e.g., diet, physical activity); and obesity-related clinical outcomes (e.g., blood pressure, blood lipids).

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: June 2013
Show search results within this document

Effectiveness of Weight Management Programs in Children and Adolescents

To examine available behavioral, pharmacological, and surgical weight management interventions for overweight (defined as BMI ≥ 85th to 94th percentile of age and sex-specific norms) and/or obese (BMI ≥ 95th percentile) children and adolescents in clinical and nonclinical community settings.

Evidence Reports/Technology Assessments - Agency for Healthcare Research and Quality (US).

Version: September 2008
Show search results within this document

Screening for Lipid Disorders in Children and Adolescents [Internet]

Dyslipidemias, disorders of lipid metabolism, are important risk factors for coronary heart disease (CHD). Identification of children with dyslipidemias could lead to interventions aimed at decreasing their risk of CHD as adults.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: July 2007
Show search results within this document

Closing the Quality Gap: Revisiting the State of the Science (Vol. 4: Medication Adherence Interventions: Comparative Effectiveness)

To assess the effectiveness of patient, provider, and systems interventions (Key Question [KQ] 1) or policy interventions (KQ 2) in improving medication adherence for an array of chronic health conditions. For interventions that are effective in improving adherence, we then assessed their effectiveness in improving health, health care utilization, and adverse events.

Evidence Reports/Technology Assessments - Agency for Healthcare Research and Quality (US).

Version: September 2012
Show search results within this document

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis

This review found that sibutramine was significantly more efficacious for achieving weight loss than orlistat, and showed a trend towards a lower dropout rate than orlistat. The possibility of bias, absence of quality assessment of the included trials and lack of participant details made the reliability of the authors' conclusions unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Long‐term effects of weight‐reducing drugs in hypertensive patients

Doctors often recommend that overweight patients with elevated blood pressure doctors lose weight and sometimes advocate taking anti‐obesity drugs to assist in weight and blood pressure reduction. However, sibutramine was withdrawn from the market in 2010 and rimonabant in 2009, making orlistat the only anti‐obesity drug to remain available. Orlistat and sibutramine have been shown to modestly reduce weight. Orlistat also reduced blood pressure but sibutramine increased blood pressure. No study investigating rimonabant was found. No evidence is available for effects of any of these drugs on death or morbidity. The most frequent side effects were gastrointestinal for orlistat and dry mouth, constipation and headache for sibutramine.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus

Obesity is closely related to type 2 diabetes and weight reduction is an important part of the care delivered to obese persons with diabetes. This review of drugs for weight loss among adults with type 2 diabetes revealed weight loss of between 2.0 and 5.1 kg for fluoxetine, orlistat and sibutramine at follow‐up of up to 57 weeks. The long‐term effects remain uncertain. Adverse events were common in all three drugs: gastrointestinal side effects with orlistat; tremor, somnolence, and sweating with fluoxetine; and palpitations with sibutramine. There were few studies examining other drugs used for weight loss in populations with diabetes.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis

This review concluded that sibutramine produced clinically meaningful reductions in body mass index for overweight and obese children and adolescents and was well tolerated. Orlistat modestly reduced body mass index with frequent gastrointestinal adverse effects. This review was generally well conducted and the authors' conclusions are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials

This meta-analysis concluded that orlistat or sibutramine therapy with behavioural modification may have a role in assisting weight loss in overweight adolescents. There was limited evidence to suggest an association with cardiovascular risk factors. Due to a lack of detail about the review methods and the risk of publication bias some caution is needed when interpreting the authors' conclusions.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Systematic Reviews in PubMed

See all (100)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...